Media coverage about Kala Pharmaceuticals (NASDAQ:KALA) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kala Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.5791180112068 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
KALA has been the subject of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $46.00 price objective on shares of Kala Pharmaceuticals in a research report on Friday, December 22nd. BidaskClub raised shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 13th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Kala Pharmaceuticals in a research report on Friday, January 5th. Finally, JPMorgan Chase & Co. set a $35.00 price objective on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $35.80.
Shares of Kala Pharmaceuticals (KALA) traded down $0.19 during mid-day trading on Monday, reaching $17.33. 107,900 shares of the company’s stock were exchanged, compared to its average volume of 407,403. Kala Pharmaceuticals has a twelve month low of $11.81 and a twelve month high of $26.75. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. The company has a market cap of $426.79 and a P/E ratio of -9.57.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.